Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
A Dose-Finding and Proof-of-Concept Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
37 participants
Feb 15, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this study is to test the safety of drug, Belantamab Mafodotin, and see what effects (good and bad) it has on people who take it and have amyloidosis, and to determine the most effective dose of the drug. The study will have 2 phases (parts). The first phase of the study will test different doses of Belantamab Mafodotin. The second phase will test Belantamab Mafodotin at the dose level found to be safe and effective in phase 1
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
2.5 mg/kg IV Belantamab mafodotin IV every 8 weeks for Part 1
1.9 mg/kg IV Belantamab mafodotin IV every 8weeks for Part 1
1.4 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
1.9 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
Belantamab mafodotin Dose 1.0 mg/kg, 1.4 mg/kg, 1.9mg/kg or 2.5mg/kg every 8 weeks or 12 weeks as determined by Part 1 recommended dosages.
1.0 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05145816